Clinical Trials Browser

Observational × Ipilimumab × Clear all

NCT07526961 2026-04-14

Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

Carcinoma, Non-Small-Cell Lung

NCT07394062 2026-02-06

ALCG-01

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06487156 2026-01-27

FINN

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Carcinoma, Renal Cell

NCT04196452 2025-11-20

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Active not recruiting

Melanoma

NCT07091695 2025-11-12

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Melanoma

NCT07215962 2025-10-14

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03963518 2025-10-06

SURROGATE-ICI

631 enrolled 6 charts

Neoplasms

NCT07024862 2025-06-17

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06627595 2024-11-15

APiTOXMM

Melanoma, Motor Activity

NCT04291755 2024-04-05

Development and Analysis of a Stool Bank for Cancer Patients

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03458455 2023-11-01

TREATMENT

Brain Neoplasms

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT03453892 2023-02-16

ST-ICI

Neoplasm Metastasis

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT05714371 2023-02-06

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma

NCT02854488 2022-03-31

Yervoy Pregnancy Surveillance Study

Melanoma

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT04136470 2020-08-10

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT04145232 2020-08-10

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03695835 2020-07-22

NIRPA

GastrointestinalGenitourinaryThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT04169867 2019-11-20

Polish Microbiome Map

Melanoma, Neoplasms

NCT03165409 2017-10-05

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Melanoma

NCT02739386 2017-04-27

Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases

Melanoma

NCT02050594 2015-07-07

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Melanoma